IRB
Expedite Study Startup: Four Strategies to Optimize Site Activation
Learn how organizations can expedite study startup by streamlining site selection, training, ethics review, and site initiation.
Canadian Medical Device Regulation 101
Canadian medical device regulations can be tricky to navigate. View this infographic to learn the REB review process for medical devices.
Let’s Get Ethical
Advarra's IRB Chairs Luke Gelinas and Amanda Higley discuss hot topics in clinical research, including cannabis studies and data ownership.
A Journey in Support of Diversity
Advarra's Sergio Armani introduces ACRP's Ride for Diversity program and why it's important to him personally and to the research community.
IRB Services for Federal Grants
View this info sheet to learn about Advarra’s IRB expert oversight and guidance to support your next federal grant proposal.
Considerations for IRB Review: Artificial Intelligence & Machine Learning
Read this blog to learn IRB review considerations for artificial intelligence and machine learning studies.
Local Versus Central IRBs: What’s the Difference?
Local IRBs and central IRBs are not really that different, although sIRB mandates have complicated things for local IRBs.
Advarra’s Support for Institutions
Find out how we keep site centricity at the forefront through our technology, services, and extraordinary team members.
Planned Emergency Research and Exception from Informed Consent
This white paper outlines considerations for those involved in planning, designing, conducting or reviewing EFIC studies
Beginner’s Guide to Institutional Review Boards (IRBs)
In the U.S., there is an independent group overseeing clinical research, ensuring participants’ rights and welfare are protected.
What Level of Review Does Your Study Need?
In this infographic, we share useful information for investigators to know which level of IRB review likely applies to their study.
Medical Devices: “Significant Risk” Versus “Nonsignificant Risk” Determinations
Take a closer look at what significant risk and nonsignificant risk determinations mean for medical device clinical trials.